Publications

Found 150 results
Type [ Year(Asc)]
2023
R Yan, V Cigliola, KA Oonk, Z Petrover, S DeLuca, DW Wolfson, A Vekstein, MA Mendiola, G Devlin, M Bishawi et al. "An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair." Cell Stem Cell 30, no. 1 (2023): 96-111.e6.
RB Fletcher, LD Stokes, IB Kelly, KM Henderson, IC Vallecillo-Viejo, JM Colazo, BV Wong, F Yu, R d'Arcy, MN Struthers et al. "Nonviral In Vivo Delivery of CRISPR-Cas9 Using Protein-Agnostic, High-Loading Porous Silicon and Polymer Nanoparticles." Acs Nano 17, no. 17 (2023): 16412-16431.
, AM Swartz, MC Brown, A Barrera, CM Amador, K Siklenka, L Humayun, JM Isaacs, TE Reddy, S Nair et al. "Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell function." bioRxiv (2023).
JH Lee, KL Shores, JJ Breithaupt, CS Lee, DM Fodera, JB Kwon, AR Ettyreddy, KM Myers, BJ Evison, AK Suchowerska et al. "PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system." Apl Bioengineering 7, no. 4 (2023).
, AM Swartz, MC Brown, A Barrera, McRoberts C Amador, K Siklenka, L Humayun, MA Ter Weele, JM Isaacs, TE Reddy et al. "Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens." Nat Genet (2023).
2022
TJ Gonzalez, KE Simon, LO Blondel, MM Fanous, AL Roger, MS Maysonet, GW Devlin, TJ Smith, DK Oh, LP Havlik et al. "Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing." Nature Communications 13, no. 1 (2022).
JP Beyersdorf, S Bawage, N Iglesias, HE Peck, RA Hobbs, JA Wroe, C Zurla, CA Gersbach, and PJ Santangelo. "Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators." Acs Nano 16, no. 4 (2022): 5660-5671.
2021
J Seo, DD Kocak, LC Bartelt, CA Williams, A Barrera, CA Gersbach, and TE Reddy. "AP-1 subunits converge promiscuously at enhancers to potentiate transcription." Genome Res 31, no. 4 (2021): 538-550.
JM Walejko, BA Christopher, SB Crown, G-F Zhang, A Pickar-Oliver, T Yoneshiro, MW Foster, S Page, S van Vliet, O Ilkayeva et al. "Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart." Nature Communications 12, no. 1 (2021).
CH Hakim, SRP Kumar, DO Pérez-López, NB Wasala, D Zhang, Y Yue, J Teixeira, X Pan, K Zhang, ED Million et al. "Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models." Nature Communications 12, no. 1 (2021).
L Wang, E Wang, Prado J Balcazar, Z Wu, K Xiang, Y Wang, Q Huang, M Negrete, K-Y Chen, W Li et al. "Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis." Advanced Science (Weinheim, Baden Wurttemberg, Germany) 8, no. 19 (2021).
JC Bodle, and CA Gersbach. "CRISPR Clocks: The Times They Are a-Changin'." The Crispr Journal 4, no. 2 (2021): 160-163.
A Pickar-Oliver, V Gough, JD Bohning, S Liu, JN Robinson-Hamm, H Daniels, WH Majoros, G Devlin, A Asokan, and CA Gersbach. "Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy." Molecular Therapy : the Journal of the American Society of Gene Therapy 29, no. 11 (2021): 3243-3257.
AA Abdeen, BD Cosgrove, CA Gersbach, and K Saha. Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science.. Vol. 23., 2021.
K Saha, EJ Sontheimer, PJ Brooks, MR Dwinell, CA Gersbach, DR Liu, SA Murray, SQ Tsai, RC Wilson, DG Anderson et al. "The NIH Somatic Cell Genome Editing program." Nature 592, no. 7853 (2021): 195-204.
MP Gemberling, K Siklenka, E Rodriguez, KR Tonn-Eisinger, A Barrera, F Liu, A Kantor, L Li, V Cigliola, MF Hazlett et al. "Transgenic mice for in vivo epigenome editing with CRISPR-based systems." Nat Methods 18, no. 8 (2021): 965-974.
2020
NVN Carullo, RA Phillips Iii, RC Simon, SAR Soto, JE Hinds, AJ Salisbury, JS Revanna, KD Bunner, L Ianov, FA Sultan et al. "Enhancer RNAs predict enhancer-gene regulatory links and are critical for enhancer function in neuronal systems." Nucleic Acids Research 48, no. 17 (2020): 9550-9570.
V Gough, and CA Gersbach. "Immunity to Cas9 as an Obstacle to Persistent Genome Editing." Molecular Therapy 28, no. 6 (2020): 1389-1391.
JB Kwon, AR Ettyreddy, A Vankara, JD Bohning, G Devlin, SD Hauschka, A Asokan, and CA Gersbach. "In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy." Molecular Therapy Methods & Clinical Development 19 (2020): 320-329.
JB Black,, S Dube, A Barrera, TS Klann, GA Rice, SS Adkar, SH Soderling, TE Reddy, and CA Gersbach. "Master Regulators and Cofactors of Human Neuronal Cell Fate Specification Identified by CRISPR Gene Activation Screens." Cell Reports 33, no. 9 (2020).
JB Kwon, A Vankara, AR Ettyreddy, JD Bohning, and CA Gersbach. "Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators." Stem Cell Reports 14, no. 5 (2020): 755-769.
K Bulaklak, and CA Gersbach. "The once and future gene therapy." Nature Communications 11, no. 1 (2020).
A Dicks, C-L Wu, N Steward, SS Adkar, CA Gersbach, and F Guilak. "Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter." Stem Cell Research & Therapy 11, no. 1 (2020).
M Mao, C-C Chang, A Pickar-Oliver, LD Cervia, L Wang, J Ji, PB Liton, CA Gersbach, and F Yuan. "Redirecting Vesicular Transport to Improve Nonviral Delivery of Molecular Cargo." Advanced Biosystems 4, no. 8 (2020).
BD Cosgrove, and CA Gersbach. "Unwinding the Role of FACT in Cas9-based Genome Editing." Molecular Cell 79, no. 3 (2020): 365-367.

Pages